Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers. The company says the data are expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback